Benchling for antibody therapeutics R&D
Antibodies are an important class of therapeutic agents which have evolved significantly over the past 30 years. Antibody R&D is now more streamlined than ever, but several factors continue to contribute to its complexity.
This data sheet discusses:
The complexities faced during both research and discovery phases
Why current solutions fail to meet these needs
How Benchling’s capabilities have helped address these challenges for leading antibody companies